Refractive

Dr. Sri Ganesh, MBBS, MS, DNB, chairman and managing director of Nethradhama Hospital Pvt. Ltd, discusses his studies on LENSAR and shares his findings.

In a presentation at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting, Marjan Farid, MD, ABO, and Preeya K. Gupta, MD, offered details of clinical trials for CSF-1 ophthalmic solution, a presbyopia eye drop candidate. Results showed that nearly half of the participants treated with CSF-1 achieved a 3-line or more increase in the distance-corrected near visual acuity an hour after drop instillation on day 15.

Shervin Korangy, CEO of BVI, shares about the company's new technology, Beyeonics One, on display during ASCRS 2022.

This advancement reinforces Alcon’s commitment to surgeon training and education, as part of the Alcon Experience Academy. The new device will be introduced at the upcoming ASCRS meeting and surgeons will be able to experience the new technology firsthand.

Three prestigious lectures are featured, including Ehud Assia, MD, from Israel who gave the ESCRS Binkhorst Lecture; Richard Packard, MD, from England who gave the Choyce Lecture to the UKISCRS; and Michael Snyder, of the Cincinnati Eye Institute in Cincinnati, Ohio, USA, who delivered the Kelman Lecture at the 2021 American Academy of Ophthalmology meeting.

Mark Packer, MD, shares his perspective on the relationship between ICL implantation or LASIK and retinal detachment.

"Tell Me Your Secrets" is the theme of the virtual April 2 event, which is expected to build on the foundation established during the first program held last fall.

Physicians find the Vivity lens offers their patients reduced glare, halos and increased spectacle independence.

Lisa M. Nijm, MD, JD, previews the program for this April 2 virtual event designed to help young ophthalmologists learn everything they need to know when starting practice.

Proper measurement of the eye is key to predicting lens strength.

Shan C. Lin, MD, explains why ophthalmologists should be mindful of refractive considerations in cataract surgery for their patients with glaucoma.

Renewed consumer interest in and demand for LASIK, SMILE, and other procedures are among the key drivers for 2021 performance.

According to investigators, patients implanted with diffractive multifocal IOLs had notable declines in the corrected distance visual acuity, distance corrected near VA, and near area of focus with aging

Cathleen McCabe, MD, discusses VUITY, the first and only FDA-approved eye drop to treat age-related blurry near vision, and how it provides opportunities for patients looking for spectacle independence.

Nasotemporal sagittal height asymmetry a good biomarker of shortsightednes.

Investigators examine usefulness in refractive surgery evaluations.

Early experience with next-generation lens engenders positive perception.

George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.

Steven Greenstein, MD, reports on the 10-year postop data from an epi-off corneal collagen cross-linking treatment in keratoconus and ectasia patients.

According to Oculus, its Myopia Master saves space and can be mounted on a workstation or an ophthalmic table. The software is operated directly via an inbuilt display.

Taking control of a practice’s future with investment, creative thinking

Colman R. Kraff, MD, shares highlights of a study evaluating the safety and efficacy of the use of the iDesign 2.0 Refractive Studio for the treatment of patients with hyperopia and myopia.

Kathryn M. Hatch, MD, details how collagen CXL is evolving with the goals of reducing complications and actually improving visual acuity.

Investigators find little difference between the options.

In recognition of Cataract Awareness Month.

Lens option can correct for surgically induced astigmatism or an inaccurate position.

Bi-sign design compensates for aberrations resulting from misalignment.

Procedure can improve best-corrected visual acuity, enhancing quality of life for patients.

Therapeutic choices beneficial for patients may be available in 1 to 3 years.

Investigators examine the demographic, refractive, PRO data measure.